Pilot feasibility study to detect mesenchymal stem cell biomarkers of bronchopulmonary dysplasia in the tracheal aspirate fluid of preterm infants

R.G. LaGrandeur, M. Singhal, F. Bany-Mohammed, C. Uy, R. Koeppel, F. Zaldivar, F. Haddad, A. Nalbandian, P. Donovan, D.M. Cooper, M. Aslam* | JNPM 2018;

OBJECTIVE: This study aimed to detect novel mesenchymal stem cell peptides/biomarkers of bronchopulmonary dysplasia (BPD) in the tracheal aspirate fluid (TAF) of preterm infants.
STUDY DESIGN: Participants included infants less than 32 weeks’ gestational age or birth weight under 1500 grams who required endotracheal intubation and mechanical ventilation within first 24 hours of life. TAF sample collection was performed at the time of the first clinically indicated routine suctioning. Standardization curves for human levels of osteopontin (Opn), macrophage colony stimulating factor 1 (Csf1), transforming growth factor beta 1 (TGF-β1), and secretory immunoglobulin A (sIgA) were generated for 15 enrolled participants.
RESULTS: We demonstrated that stem cell biomarkers are secreted into the TAF of preterm infants and their concentrations can be easily measured during the first week of life.
CONCLUSIONS: Further studies are warranted to determine a causal relationship between these biomarkers and BPD development and severity.

*Corresponding Author: 

Muhammad Aslam, Associate Professor of Pediatrics, Division of Neonatology, University of California Irvine, UC Irvine Medical Center, 101 The City Drive South, Bldg 56, Ste 600, Orange, CA 92868, USA. Tel.: +1 714 456 6933; Fax: +1 714 456 7658; E-mail: maslam@uci.edu.